Clinical trials: Dementia, completed
Progressive Supranuclear Palsy, Alzheimer Disease
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
The overall goal of this imaging trial is to evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.
- Conditions
- Progressive Supranuclear Palsy, Alzheimer Disease, Healthy Volunteers
- Trial name
- NCT03080051
- Testing
- [18F]MNI-952, [18F]Florbetapir
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Dementia, Stress
Stress Management Toolkit for People Living With Dementia and Their Care Partners
The purpose of this study is to develop a prototype of a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home.
- Conditions
- Dementia, Stress, Caregiver Burden
- Trial name
- NCT05465551
- Testing
- Stress Management Toolkit
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Duke University
Mild Cognitive Impairment, Alzheimer's Disease
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically…
- Trial name
- NCT01028053
- Testing
- Flutemetamol (18F) Injection
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- GE Healthcare
Huntington Disease
Is Caffeine an Environmental Modifier in Huntington's Disease?
The aim of the study is to establish if caffeine consumption is associated with the evolution of the disease in premanifest HD.
- Trial name
- CrEAM-HD (NCT03034122)
- Where
- 10 sites in France
- Volunteers
- 77 people
- Sponsor
- University Hospital, Lille
Delirium, Alzheimer Disease
Improving the Recovery and Outcome Every Day After the ICU
Primary Specific Aim: Determine the effect of the combined physical exercise and cognitive training on the cognitive function of ICU survivors aged 50 and older.
- Trial name
- IMPROVE (NCT03095417)
- Testing
- Physical Exercise Intervention, Cognitive Training Intervention, Stretching Control
- Where
- 6 sites in United States
- Volunteers
- 249 people
- Sponsor
- Indiana University
Type 2 Diabetes Mellitus, Cognitive Impairment
Intensive Aerobic and Resistance Exercise Program (IAREP)
A 12-week Intensive Aerobic and Resistance Exercise Program (IAREP) intervention was implemented on high-risk and low-risk subjects with cognitive impairment in type 2 Diabetes Mellitus.
- Conditions
- Type 2 Diabetes Mellitus, Cognitive Impairment, Non-insulin-dependent Diabetes Mellitus, Cognitive Dysfunction
- Trial name
- NCT06401733
- Testing
- Intensive Aerobic and Resistance Exercise Program (IAREP)
- Where
- Singapore
- Volunteers
- 58 people
- Sponsor
- National University of Singapore
Alzheimer's Disease in Down Syndrome
Goal Attainment Scaling (GAS) Sub-Study
This is an optional sub-study that will enroll participants from LIFE-DSR parent protocol. The aim is to assess change over 16 months in individuals with Down syndrome through individualized goals set by their caregivers.
- Trial name
- NCT06484426
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- LuMind IDSC Foundation
Dementia Alzheimers
Alzheimer's Family Caregiver Intervention in Vietnam
This is a single arm pilot study of 6-8 families to test the feasibility and acceptability of a Alzheimer's family caregiver intervention in Vietnam.
- Trial name
- NCT03100617
- Testing
- Psychosocial caregiver intervention
- Where
- Vietnam
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Dementia
Education Program for Enhancing Healthcare Students' Attitudes Toward People Living With Dementia
The aim of this single-arm pre-post study is to examine the effectiveness of gaming-based dementia educational programs for enhancing healthcare students' attitudes toward people living with dementia (PLWD).
- Trial name
- NCT06122623
- Testing
- Health Education
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Universitas Airlangga
Alzheimer Disease
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
- Trial name
- NCT00568776
- Testing
- ELND005
- Where
- 62 sites in United States, Canada
- Volunteers
- 353 people
- Sponsor
- OPKO Health, Inc.
Irritable Mood, Aggression
Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability
The purpose of this study is to determine if amantadine hydrochloride given 100 mg in the morning and at noon is safe and effective in the treatment of mood and behavior changes (i.e.
- Conditions
- Irritable Mood, Aggression, Traumatic Brain Injury
- Trial name
- NCT00627250
- Testing
- Amantadine
- Volunteers
- 76 people
- Sponsor
- Wake Forest University Health Sciences
Low Back Pain
Internet App to Self-Manage Occasional Low Back Pain
Nonspecific low back pain (NLBP) is the diagnosis for 85% of low back pain sufferers with no underlying medical cause (e.g., herniated disc, spinal stenosis) that requires physician care.
- Trial name
- BackPain2 (NCT01950091)
- Testing
- FitBack on-line intervention, Alternative Website Control
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- Oregon Center for Applied Science, Inc.
Alzheimer's Disease
Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease
This phase 2 study was designed to evaluate the activity of oral masitinib (AB1010) administered at 2 dose levels during 24 weeks to patients with mild to moderate confirmed Alzheimer's type disease.
- Trial name
- NCT00976118
- Testing
- masitinib (AB1010)
- Volunteers
- 34 people
- Sponsor
- AB Science
Mild Cognitive Impairment, Major Depressive Disorder
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown.
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
- Trial name
- NCT01876823
- Testing
- es-citalopram, Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Dementia, Alzheimer's Disease
Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease
The purpose of this observational study is to examine patterns of treatment care for patients with Alzheimer's disease (AD) in a real-world arena and to examine the association with different outcomes for patients and informal…
- Trial name
- REMIND (NCT00283725)
- Testing
- No intervention
- Volunteers
- 573 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Dementia, Dementia, Vascular
Feasibility of the SmartPrompt for Improving Everyday Function in Dementia
Difficulty completing everyday tasks is a primary reason for the high cost of care, loss of caregiver paid hours, and general caregiver burden associated with dementia.
- Conditions
- Dementia, Dementia, Vascular, Dementia Alzheimers, Dementia, Mixed
- Trial name
- SmartPrompt (NCT04313582)
- Testing
- SmartPrompt smartphone application
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Temple University
Prader-Willi Syndrome, Aggression
Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
This is a placebo-controlled clinical trial to assess whether Guanfacine Extended Release (GXR) reduces aggression and self injurious behavior in individuals with Prader Willi Syndrome (PWS).
- Conditions
- Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes
- Trial name
- PWS-GXR (NCT05657860)
- Testing
- Guanfacine Extended Release
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Maimonides Medical Center
Dementia Alzheimers
ImGTS for Patients With Behavioral and Psychological Symptoms of Dementia
The proposed research project aims to answer the question "Are immersive technology systems effective in the management and treatment of patients with BPSD?".
- Trial name
- NCT05265182
- Testing
- virtual reality
- Where
- Philippines
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Augmented eXperience E-health Laboratory
Healthy Subjects
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.
- Trial name
- NCT02509117
- Testing
- PF-06751979 single ascending dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Pfizer
Neurodegenerative Diseases, Memory Disturbances
Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease
Background: New research criteria for the diagnosis of Alzheimer's disease (AD) have recently been developed to enable an early diagnosis of AD pathophysiology by relying on emerging biomarkers.
- Trial name
- NCT01450891
- Where
- 4 sites in Netherlands
- Volunteers
- 304 people
- Sponsor
- Maastricht University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.